Gene symbol   |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
Aicda | |
NM_009645 |
activation-induced cytidine deaminase (Aicda), mRNA [NM_009645] |
KLA | 1.01 |
.99 |
.98 |
1.05 |
1.03 |
.99 |
1.17 |
| ATP | .95 |
1.02 |
.99 |
1.02 |
.94 |
1.34 |
1.09 |
| KLA/ATP | 1.05 |
.98 |
1.05 |
1.06 |
1.05 |
1.79 |
1.35 |
|
AK044424
| |
AK044424 |
adult retina cDNA, RIKEN full-length enriched library, clone:A930012B14 product:unclassifiable, full insert sequence [AK044424] |
KLA | .92 |
.86 |
.88 |
.88 |
.95 |
.83 |
1.05 |
| ATP | .85 |
.68 |
.74 |
.72 |
.83 |
1.06 |
1.04 |
| KLA/ATP | .86 |
.74 |
.78 |
.74 |
.80 |
.99 |
1.07 |
|
Ccl25 | |
NM_009138 |
chemokine (C-C motif) ligand 25 (Ccl25), mRNA [NM_009138] |
KLA | 1.12 |
1.13 |
1.03 |
1.14 |
1.19 |
1.50 |
1.35 |
| ATP | .97 |
.97 |
1.18 |
1.05 |
1.23 |
1.49 |
1.15 |
| KLA/ATP | 1.10 |
1.21 |
1.32 |
1.14 |
1.66 |
1.98 |
1.70 |
|
Ccl28 | |
NM_020279 |
chemokine (C-C motif) ligand 28 (Ccl28), mRNA [NM_020279] |
KLA | .94 |
1.04 |
.95 |
1.00 |
.95 |
1.04 |
1.06 |
| ATP | 1.04 |
.98 |
1.01 |
.99 |
1.05 |
.99 |
1.09 |
| KLA/ATP | .98 |
.95 |
.95 |
1.03 |
1.06 |
.97 |
1.00 |
|
Ccr10 | |
NM_007721 |
chemokine (C-C motif) receptor 10 (Ccr10), mRNA [NM_007721] |
KLA | 1.09 |
1.12 |
1.05 |
1.03 |
1.15 |
.97 |
.96 |
| ATP | .90 |
1.01 |
.97 |
.97 |
.98 |
1.02 |
1.00 |
| KLA/ATP | .97 |
.99 |
1.04 |
1.02 |
.97 |
.92 |
.97 |
|
Ccr9 | |
NM_009913 |
chemokine (C-C motif) receptor 9 (Ccr9), mRNA [NM_009913] |
KLA | 1.49 |
1.42 |
1.94 |
1.73 |
1.61 |
1.31 |
1.26 |
| ATP | 1.19 |
1.03 |
1.17 |
1.26 |
1.34 |
1.41 |
1.12 |
| KLA/ATP | 1.58 |
1.64 |
1.64 |
1.64 |
1.40 |
1.41 |
1.42 |
|
Cd28 | |
NM_007642 |
CD28 antigen (Cd28), mRNA [NM_007642] |
KLA | .52 |
.51 |
.45 |
.50 |
.36 |
.33 |
.18 |
| ATP | 1.11 |
1.26 |
1.08 |
1.25 |
1.99 |
1.42 |
2.08 |
| KLA/ATP | .51 |
.51 |
.58 |
.60 |
.56 |
.53 |
.38 |
|
Cd40 | |
NM_170701 |
CD40 antigen (Cd40), transcript variant 3, mRNA [NM_170701] |
KLA | 23.87 |
23.62 |
23.26 |
23.98 |
22.07 |
17.37 |
5.34 |
| ATP | 1.00 |
1.01 |
1.06 |
2.96 |
2.65 |
3.03 |
1.70 |
| KLA/ATP | 22.77 |
23.79 |
29.67 |
28.85 |
28.08 |
21.62 |
13.02 |
|
Cd40lg | |
NM_011616 |
CD40 ligand (Cd40lg), mRNA [NM_011616] |
KLA | 1.03 |
1.07 |
1.02 |
.98 |
1.06 |
1.06 |
1.03 |
| ATP | .95 |
.92 |
.99 |
1.06 |
1.02 |
1.04 |
1.07 |
| KLA/ATP | 1.00 |
1.01 |
.93 |
1.04 |
.94 |
1.01 |
.98 |
|
Cd80 | |
NM_009855 |
CD80 antigen (Cd80), mRNA [NM_009855] |
KLA | 2.13 |
1.91 |
1.89 |
1.78 |
1.29 |
1.00 |
.82 |
| ATP | .99 |
1.20 |
1.98 |
1.49 |
1.37 |
2.40 |
1.71 |
| KLA/ATP | 2.05 |
2.32 |
3.09 |
2.27 |
1.95 |
2.89 |
3.07 |
|
Cd86 | |
NM_019388 |
CD86 antigen (Cd86), mRNA [NM_019388] |
KLA | 13.80 |
14.41 |
18.21 |
18.33 |
17.37 |
17.26 |
4.82 |
| ATP | 1.02 |
1.00 |
2.20 |
3.64 |
5.16 |
6.79 |
3.81 |
| KLA/ATP | 14.80 |
14.66 |
18.10 |
18.96 |
19.38 |
20.42 |
14.21 |
|
Cxcl12 | |
NM_001012477 |
chemokine (C-X-C motif) ligand 12 (Cxcl12), transcript variant 3, mRNA [NM_001012477] |
KLA | .91 |
.91 |
.92 |
.92 |
.91 |
1.00 |
.85 |
| ATP | 1.00 |
.99 |
1.02 |
.99 |
.91 |
.93 |
.88 |
| KLA/ATP | .89 |
.91 |
.97 |
.97 |
.94 |
.93 |
.82 |
|
Cxcl12 | |
NM_021704 |
chemokine (C-X-C motif) ligand 12 (Cxcl12), transcript variant 1, mRNA [NM_021704] |
KLA | 1.01 |
.96 |
1.04 |
1.04 |
.94 |
.98 |
.94 |
| ATP | 1.01 |
.92 |
.98 |
1.04 |
1.02 |
.94 |
.98 |
| KLA/ATP | 1.02 |
.98 |
1.07 |
.95 |
1.02 |
.98 |
.99 |
|
Cxcr4 | |
NM_009911 |
chemokine (C-X-C motif) receptor 4 (Cxcr4), mRNA [NM_009911] |
KLA | .30 |
.34 |
.26 |
.31 |
.25 |
.29 |
.42 |
| ATP | 1.27 |
2.70 |
6.37 |
11.61 |
7.04 |
1.14 |
4.92 |
| KLA/ATP | .28 |
.34 |
.56 |
2.60 |
3.47 |
1.23 |
1.28 |
|
EG629860
| |
M17953 |
gb|Mouse Ig rearranged H-chain V-region mRNA VJ1 [M17953] |
KLA | .96 |
1.05 |
1.03 |
1.08 |
1.08 |
1.02 |
.98 |
| ATP | .97 |
.99 |
1.05 |
1.10 |
.95 |
.94 |
.91 |
| KLA/ATP | .96 |
.94 |
.97 |
1.04 |
.97 |
1.01 |
.89 |
|
H2-Aa | |
NM_010378 |
histocompatibility 2, class II antigen A, alpha (H2-Aa), mRNA [NM_010378] |
KLA | 1.43 |
1.59 |
1.68 |
1.50 |
1.62 |
1.89 |
1.64 |
| ATP | 1.07 |
1.15 |
1.27 |
1.90 |
1.92 |
1.77 |
1.55 |
| KLA/ATP | 1.62 |
1.81 |
1.74 |
2.29 |
1.89 |
1.92 |
2.19 |
|
H2-Ab1 | |
BC010322 |
histocompatibility 2, class II antigen A, beta 1, mRNA (cDNA clone MGC:6297 IMAGE:2651058), complete cds [BC010322] |
KLA | 1.73 |
1.76 |
1.77 |
1.55 |
1.95 |
2.10 |
2.27 |
| ATP | 1.03 |
1.18 |
1.32 |
1.99 |
1.79 |
1.56 |
1.61 |
| KLA/ATP | 1.70 |
2.01 |
1.74 |
2.52 |
1.58 |
2.01 |
2.75 |
|
H2-Ab1 | |
NM_207105 |
histocompatibility 2, class II antigen A, beta 1 (H2-Ab1), mRNA [NM_207105] |
KLA | 2.02 |
2.15 |
2.07 |
2.09 |
2.32 |
2.78 |
3.08 |
| ATP | 1.11 |
1.20 |
1.42 |
2.33 |
2.33 |
2.25 |
1.87 |
| KLA/ATP | 2.11 |
2.32 |
2.52 |
3.62 |
2.67 |
2.96 |
5.04 |
|
H2-DMa | |
NM_010386 |
histocompatibility 2, class II, locus DMa (H2-DMa), mRNA [NM_010386] |
KLA | 1.49 |
1.50 |
1.65 |
1.65 |
1.91 |
2.23 |
1.69 |
| ATP | 1.04 |
1.12 |
1.26 |
1.67 |
1.24 |
.99 |
1.32 |
| KLA/ATP | 1.58 |
1.68 |
1.70 |
2.02 |
1.37 |
1.35 |
1.90 |
|
H2-DMb1 | |
NM_010387 |
histocompatibility 2, class II, locus Mb1 (H2-DMb1), mRNA [NM_010387] |
KLA | 1.06 |
1.14 |
1.08 |
1.13 |
1.24 |
1.41 |
1.37 |
| ATP | 1.01 |
1.02 |
1.09 |
1.14 |
.92 |
.73 |
1.36 |
| KLA/ATP | 1.13 |
1.05 |
1.21 |
1.17 |
.98 |
.83 |
1.41 |
|
H2-DMb2 | |
NM_010388 |
histocompatibility 2, class II, locus Mb2 (H2-DMb2), mRNA [NM_010388] |
KLA | 1.00 |
1.04 |
.93 |
.95 |
.96 |
.95 |
1.03 |
| ATP | 1.06 |
1.04 |
.94 |
.92 |
.97 |
.95 |
1.00 |
| KLA/ATP | .90 |
.94 |
.99 |
.94 |
.90 |
.96 |
.92 |
|
H2-Eb1 | |
X52641 |
gb|Mouse mRNA for I-A beta NOD. [X52641] |
KLA | 1.94 |
2.06 |
1.94 |
1.87 |
1.96 |
2.18 |
1.76 |
| ATP | 1.11 |
1.20 |
1.53 |
2.70 |
3.02 |
2.91 |
1.40 |
| KLA/ATP | 2.09 |
2.11 |
2.26 |
3.55 |
2.76 |
3.05 |
3.05 |
|
H2-Oa | |
NM_008206 |
histocompatibility 2, O region alpha locus (H2-Oa), mRNA [NM_008206] |
KLA | 1.22 |
1.32 |
1.37 |
1.33 |
1.31 |
1.26 |
1.53 |
| ATP | 1.02 |
1.05 |
1.16 |
1.21 |
1.12 |
1.07 |
1.16 |
| KLA/ATP | 1.32 |
1.34 |
1.31 |
1.34 |
1.25 |
1.35 |
2.78 |
|
H2-Ob | |
NM_010389 |
histocompatibility 2, O region beta locus (H2-Ob), mRNA [NM_010389] |
KLA | 1.05 |
1.07 |
1.01 |
.96 |
1.10 |
1.02 |
1.00 |
| ATP | 1.04 |
.99 |
1.00 |
1.03 |
.94 |
1.07 |
.94 |
| KLA/ATP | 1.02 |
.97 |
1.06 |
1.08 |
1.00 |
.96 |
1.05 |
|
Icos | |
AK030827 |
adult male thymus cDNA, RIKEN full-length enriched library, clone:5830414M16 product:inducible T-cell co-stimulator, full insert sequence [AK030827] |
KLA | .99 |
.91 |
.97 |
.99 |
.94 |
.90 |
.78 |
| ATP | 1.06 |
.97 |
1.03 |
.88 |
.90 |
.91 |
.79 |
| KLA/ATP | .92 |
.99 |
.98 |
.97 |
.95 |
.90 |
.80 |
|
Icos | |
NM_017480 |
inducible T-cell co-stimulator (Icos), mRNA [NM_017480] |
KLA | 1.01 |
.96 |
.86 |
.95 |
.92 |
.91 |
.84 |
| ATP | .99 |
1.05 |
1.00 |
.98 |
.96 |
.97 |
.86 |
| KLA/ATP | .95 |
.98 |
.94 |
1.00 |
.96 |
.88 |
.87 |
|
Icosl | |
NM_015790 |
icos ligand (Icosl), mRNA [NM_015790] |
KLA | 3.89 |
3.36 |
2.85 |
2.20 |
1.82 |
1.29 |
.91 |
| ATP | 1.07 |
1.04 |
1.27 |
1.54 |
1.36 |
1.34 |
.57 |
| KLA/ATP | 3.24 |
3.83 |
4.40 |
3.17 |
1.62 |
1.53 |
.96 |
|
Igh-VJ55 8 | |
AY547436 |
immunoglobulin heavy chain VDJ region mRNA, partial cds [AY547436] |
KLA | 1.06 |
1.05 |
1.01 |
.93 |
1.03 |
.96 |
.93 |
| ATP | .99 |
1.00 |
1.06 |
.95 |
.96 |
1.06 |
1.05 |
| KLA/ATP | .98 |
.94 |
1.07 |
.95 |
.97 |
.99 |
1.02 |
|
Igh-VJ55 8 | |
CA578712 |
gb|K0727F04-5N NIA Mouse Hematopoietic Stem Cell (Lin- [CA578712] |
KLA | .99 |
.94 |
1.01 |
1.10 |
.93 |
.97 |
.92 |
| ATP | .93 |
1.04 |
1.01 |
.98 |
1.05 |
.96 |
.95 |
| KLA/ATP | .99 |
.95 |
.95 |
.98 |
1.02 |
.98 |
.95 |
|
Igh-VJ55 8 | |
ENSMUST00000103412 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHA] [ENSMUST00000103412] |
KLA | 1.01 |
.97 |
1.20 |
1.01 |
.98 |
1.44 |
1.24 |
| ATP | .99 |
.98 |
1.07 |
1.03 |
1.00 |
1.01 |
1.21 |
| KLA/ATP | .99 |
1.02 |
.96 |
1.03 |
.97 |
1.13 |
1.30 |
|
Igh-VJ55 8 | |
ENSMUST00000103413 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHE] [ENSMUST00000103413] |
KLA | 1.00 |
.99 |
1.06 |
1.06 |
.99 |
1.03 |
1.02 |
| ATP | 1.08 |
1.06 |
1.06 |
1.06 |
1.02 |
1.06 |
.95 |
| KLA/ATP | 1.00 |
1.04 |
1.09 |
1.02 |
1.06 |
1.02 |
.95 |
|
Igh-VJ55 8 | |
U39781 |
J558+ IgM heavy chain mRNA, hybridoma clone ME2B7, partial cds. [U39781] |
KLA | .93 |
.89 |
.98 |
.97 |
1.03 |
1.00 |
.94 |
| ATP | 1.04 |
1.02 |
1.08 |
.94 |
.93 |
.90 |
.79 |
| KLA/ATP | .88 |
.89 |
.97 |
.93 |
.88 |
.92 |
.82 |
|
Il10 | |
NM_010548 |
interleukin 10 (Il10), mRNA [NM_010548] |
KLA | 17.59 |
18.64 |
22.22 |
23.06 |
11.83 |
8.27 |
2.07 |
| ATP | 1.86 |
3.22 |
7.72 |
20.51 |
25.86 |
8.38 |
1.01 |
| KLA/ATP | 17.91 |
23.49 |
34.53 |
34.48 |
20.98 |
12.03 |
8.17 |
|
Il15 | |
AB022307 |
mRNA for shorter isoform of interleukin 15, partial cds. [AB022307] |
KLA | 13.11 |
12.14 |
12.05 |
8.72 |
4.50 |
3.62 |
1.70 |
| ATP | 1.04 |
1.05 |
1.94 |
1.72 |
1.74 |
3.48 |
1.69 |
| KLA/ATP | 13.23 |
13.71 |
21.01 |
21.43 |
21.51 |
10.85 |
4.55 |
|
Il15 | |
NM_008357 |
interleukin 15 (Il15), mRNA [NM_008357] |
KLA | 28.44 |
24.75 |
23.34 |
20.83 |
11.02 |
7.27 |
2.51 |
| ATP | 1.00 |
.96 |
1.22 |
1.21 |
1.24 |
4.27 |
1.85 |
| KLA/ATP | 24.24 |
23.93 |
33.47 |
31.76 |
21.73 |
10.79 |
11.23 |
|
Il15ra | |
NM_008358 |
interleukin 15 receptor, alpha chain (Il15ra), transcript variant 1, mRNA [NM_008358] |
KLA | 8.74 |
9.57 |
10.15 |
8.79 |
7.56 |
7.63 |
3.77 |
| ATP | .96 |
.93 |
1.02 |
1.07 |
2.02 |
3.73 |
1.46 |
| KLA/ATP | 9.56 |
10.41 |
10.94 |
10.62 |
11.08 |
9.82 |
8.07 |
|
Il2 | |
NM_008366 |
interleukin 2 (Il2), mRNA [NM_008366] |
KLA | .96 |
.97 |
.96 |
1.00 |
.97 |
.97 |
.99 |
| ATP | 1.04 |
1.02 |
1.00 |
1.03 |
.97 |
.98 |
.97 |
| KLA/ATP | 1.01 |
.98 |
.97 |
1.00 |
.97 |
.97 |
.96 |
|
Il4 | |
NM_021283 |
interleukin 4 (Il4), mRNA [NM_021283] |
KLA | .94 |
.95 |
.91 |
.94 |
.91 |
.94 |
1.07 |
| ATP | 1.02 |
1.06 |
1.05 |
1.22 |
1.12 |
1.10 |
1.26 |
| KLA/ATP | .92 |
.96 |
.93 |
1.08 |
.98 |
1.03 |
1.18 |
|
Il5 | |
NM_010558 |
interleukin 5 (Il5), mRNA [NM_010558] |
KLA | 1.10 |
1.11 |
1.10 |
.98 |
1.01 |
.98 |
.97 |
| ATP | .94 |
1.04 |
1.08 |
.92 |
.97 |
1.02 |
1.03 |
| KLA/ATP | .98 |
.92 |
1.12 |
1.03 |
1.02 |
1.00 |
1.03 |
|
Il6 | |
NM_031168 |
interleukin 6 (Il6), mRNA [NM_031168] |
KLA | 352.99 |
378.70 |
276.81 |
168.47 |
59.99 |
18.66 |
8.27 |
| ATP | 1.04 |
1.08 |
2.28 |
3.69 |
30.40 |
161.93 |
2.11 |
| KLA/ATP | 334.28 |
528.66 |
###.## |
935.86 |
302.45 |
355.36 |
99.65 |
|
Itga4 | |
NM_010576 |
integrin alpha 4 (Itga4), mRNA [NM_010576] |
KLA | 4.65 |
4.83 |
4.47 |
3.76 |
2.93 |
1.65 |
1.01 |
| ATP | 1.10 |
1.12 |
1.17 |
1.08 |
.86 |
.75 |
.36 |
| KLA/ATP | 4.82 |
5.02 |
4.43 |
3.69 |
2.11 |
1.13 |
.79 |
|
Itgb7 | |
NM_013566 |
integrin beta 7 (Itgb7), mRNA [NM_013566] |
KLA | .91 |
.88 |
.93 |
1.19 |
.93 |
.76 |
.79 |
| ATP | 1.00 |
.96 |
1.30 |
1.44 |
2.84 |
3.07 |
7.90 |
| KLA/ATP | .96 |
1.05 |
1.35 |
1.20 |
2.70 |
3.53 |
8.17 |
|
Ltbr | |
NM_010736 |
lymphotoxin B receptor (Ltbr), mRNA [NM_010736] |
KLA | .78 |
.77 |
.80 |
.95 |
1.08 |
1.39 |
1.36 |
| ATP | .94 |
.86 |
1.00 |
.83 |
.74 |
1.18 |
1.37 |
| KLA/ATP | .69 |
.71 |
.74 |
.68 |
.85 |
1.04 |
1.69 |
|
Madcam1 | |
NM_013591 |
mucosal vascular addressin cell adhesion molecule 1 (Madcam1), mRNA [NM_013591] |
KLA | .98 |
1.03 |
1.03 |
1.00 |
.99 |
.98 |
1.04 |
| ATP | .87 |
1.01 |
1.01 |
1.02 |
.95 |
1.04 |
.94 |
| KLA/ATP | 1.04 |
1.16 |
1.03 |
1.01 |
.97 |
.92 |
.95 |
|
Map3k14 | |
NM_016896 |
mitogen-activated protein kinase kinase kinase 14 (Map3k14), mRNA [NM_016896] |
KLA | .32 |
.30 |
.40 |
.52 |
1.08 |
1.14 |
.94 |
| ATP | 1.18 |
1.24 |
1.13 |
.85 |
.82 |
.84 |
.99 |
| KLA/ATP | .33 |
.30 |
.34 |
.50 |
1.02 |
.84 |
1.43 |
|
Mm.15898 1 | |
142388182 |
Unknown |
KLA | .25 |
.22 |
.31 |
.50 |
.85 |
1.11 |
.83 |
| ATP | 1.02 |
.94 |
1.31 |
.76 |
.73 |
.96 |
.92 |
| KLA/ATP | .24 |
.22 |
.34 |
.38 |
1.16 |
.96 |
1.23 |
|
Mm.24004 7 | |
118130430 |
Unknown |
KLA | 1.09 |
1.07 |
1.01 |
1.00 |
1.04 |
1.05 |
.97 |
| ATP | .98 |
1.00 |
1.05 |
.97 |
1.05 |
1.02 |
1.05 |
| KLA/ATP | .98 |
1.04 |
1.16 |
1.06 |
1.06 |
.96 |
1.02 |
|
Mm.25500 3 | |
161484596 |
Unknown |
KLA | .35 |
.34 |
.35 |
.34 |
.22 |
.19 |
.10 |
| ATP | 1.09 |
1.27 |
1.13 |
1.29 |
2.25 |
1.66 |
2.22 |
| KLA/ATP | .38 |
.36 |
.39 |
.40 |
.49 |
.42 |
.32 |
|
Mm.874 | |
6754317 |
Unknown |
KLA | 24.98 |
24.87 |
26.43 |
39.61 |
12.88 |
8.64 |
1.63 |
| ATP | 1.97 |
3.50 |
11.05 |
28.47 |
38.30 |
10.44 |
.65 |
| KLA/ATP | 23.45 |
29.37 |
58.52 |
51.77 |
30.64 |
14.61 |
8.63 |
|
Mm.8983 | |
77627742 |
Unknown |
KLA | .89 |
.94 |
.87 |
.83 |
.73 |
.60 |
.41 |
| ATP | 1.02 |
1.06 |
1.14 |
1.28 |
1.11 |
.76 |
.55 |
| KLA/ATP | 1.00 |
.98 |
1.03 |
1.19 |
1.01 |
.70 |
.54 |
|
Pigr | |
NM_011082 |
polymeric immunoglobulin receptor (Pigr), mRNA [NM_011082] |
KLA | .93 |
.98 |
1.04 |
.95 |
1.05 |
1.05 |
1.03 |
| ATP | 1.10 |
.96 |
1.03 |
1.09 |
1.01 |
1.02 |
1.04 |
| KLA/ATP | .97 |
1.01 |
.99 |
1.05 |
1.11 |
1.12 |
1.07 |
|
Tgfb1 | |
NM_011577 |
transforming growth factor, beta 1 (Tgfb1), mRNA [NM_011577] |
KLA | .87 |
.89 |
.90 |
.70 |
.83 |
.77 |
1.12 |
| ATP | 1.20 |
1.41 |
.80 |
1.49 |
1.11 |
.93 |
.99 |
| KLA/ATP | 1.10 |
1.20 |
.53 |
1.05 |
.66 |
.85 |
.90 |
|
Tnfrsf13 b | |
AK155178 |
NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F630206K19 product:tumor necrosis factor receptor superfamily, member 13b, full insert sequence [AK155178] |
KLA | .49 |
.51 |
.50 |
.49 |
.55 |
.72 |
.66 |
| ATP | 1.01 |
1.08 |
1.16 |
1.27 |
.78 |
.28 |
.69 |
| KLA/ATP | .50 |
.54 |
.52 |
.54 |
.35 |
.28 |
.64 |
|
Tnfrsf13 b | |
NM_021349 |
tumor necrosis factor receptor superfamily, member 13b (Tnfrsf13b), mRNA [NM_021349] |
KLA | .85 |
.87 |
.83 |
.83 |
.89 |
.90 |
.90 |
| ATP | .96 |
.96 |
1.00 |
.98 |
.80 |
.75 |
.91 |
| KLA/ATP | .85 |
.87 |
.84 |
.88 |
.77 |
.84 |
.87 |
|
Tnfrsf13 c | |
NM_028075 |
tumor necrosis factor receptor superfamily, member 13c (Tnfrsf13c), mRNA [NM_028075] |
KLA | 1.05 |
1.04 |
1.05 |
1.01 |
1.05 |
1.00 |
.92 |
| ATP | 1.03 |
1.01 |
1.01 |
.99 |
1.04 |
1.03 |
1.04 |
| KLA/ATP | 1.05 |
1.07 |
1.10 |
1.04 |
1.02 |
.94 |
1.00 |
|
Tnfrsf17
| |
NM_011608 |
tumor necrosis factor receptor superfamily, member 17 (Tnfrsf17), mRNA [NM_011608] |
KLA | .94 |
.89 |
.91 |
.93 |
.92 |
.80 |
.66 |
| ATP | .98 |
.94 |
1.02 |
.96 |
.94 |
.87 |
.71 |
| KLA/ATP | .97 |
.87 |
.94 |
.94 |
.96 |
.86 |
.66 |
|
Tnfsf12- tnfsf13 | |
NM_001034097 |
tumor necrosis factor (ligand) superfamily, member 12-member 13 (Tnfsf12-tnfsf13), transcript variant 1, mRNA [NM_001034097] |
KLA | .74 |
.74 |
.73 |
.64 |
.54 |
.42 |
.35 |
| ATP | .96 |
.99 |
1.06 |
1.25 |
1.11 |
.94 |
.61 |
| KLA/ATP | .76 |
.77 |
.76 |
.99 |
.86 |
.82 |
.55 |
|
Tnfsf13b
| |
ENSMUST00000033892 |
ens|Tumor necrosis factor ligand superfamily member 13B (B cell-activating factor) (BAFF) (CD257 antigen) [Contains: Tumor necrosis factor ligand superfamily member 13b, membrane form; Tumor necrosis factor ligand superfamily member 13b, soluble form]. [ |
KLA | .95 |
.99 |
.93 |
.92 |
.94 |
.94 |
.92 |
| ATP | .90 |
.92 |
1.01 |
.91 |
.93 |
.95 |
.92 |
| KLA/ATP | .94 |
.89 |
1.17 |
1.03 |
.98 |
.93 |
.90 |
|
Tnfsf13b
| |
NM_033622 |
tumor necrosis factor (ligand) superfamily, member 13b (Tnfsf13b), mRNA [NM_033622] |
KLA | .87 |
.87 |
.92 |
.79 |
.74 |
.80 |
1.17 |
| ATP | .97 |
.87 |
.83 |
.81 |
.79 |
.57 |
.38 |
| KLA/ATP | .91 |
.86 |
.87 |
.88 |
1.02 |
.89 |
.49 |
|